$KALV
KalVista Pharmaceuticals, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022018239 Filed on September 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2021 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.130M $5.847M
YoY Change 39.05% 78.26%
% of Gross Profit
Research & Development $18.19M $13.67M
YoY Change 33.05% 22.37%
% of Gross Profit
Depreciation & Amortization $158.0K $132.0K
YoY Change 19.7% 3.13%
% of Gross Profit
Operating Expenses $26.32M $19.52M
YoY Change 34.84% 35.15%
Operating Profit -$26.32M -$19.52M
YoY Change 34.84%
Interest Expense -$275.0K $223.0K
YoY Change -223.32% -68.14%
% of Operating Profit
Other Income/Expense, Net $3.274M $3.184M
YoY Change 2.83% 8.67%
Pretax Income -$23.04M -$16.11M
YoY Change 43.04% 49.02%
Income Tax
% Of Pretax Income
Net Earnings -$23.04M -$16.11M
YoY Change 43.04% 48.96%
Net Earnings / Revenue
Basic Earnings Per Share -$0.94 -$0.66
Diluted Earnings Per Share -$0.94 -$659.4K
COMMON SHARES
Basic Shares Outstanding 24.57M 24.44M
Diluted Shares Outstanding 24.56M 24.43M

Balance Sheet

Concept 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $142.1M $230.6M
YoY Change -38.4% 258.68%
Cash & Equivalents $37.86M $48.34M
Short-Term Investments $104.2M $182.3M
Other Short-Term Assets $11.08M $5.538M
YoY Change 100.14% 67.82%
Inventory
Prepaid Expenses $6.709M
Receivables
Other Receivables
Total Short-Term Assets $170.4M $249.8M
YoY Change -31.78% 211.45%
LONG-TERM ASSETS
Property, Plant & Equipment $3.030M $9.151M
YoY Change -66.89% 161.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $218.0K $200.0K
YoY Change 9.0% 0.0%
Total Long-Term Assets $11.91M $9.351M
YoY Change 27.39% 152.59%
TOTAL ASSETS
Total Short-Term Assets $170.4M $249.8M
Total Long-Term Assets $11.91M $9.351M
Total Assets $182.3M $259.1M
YoY Change -29.64% 208.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.908M $1.448M
YoY Change 100.83% -19.56%
Accrued Expenses $5.828M $5.876M
YoY Change -0.82% -12.3%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.733M $8.229M
YoY Change 18.28% -3.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $8.014M $6.474M
YoY Change 23.79% 547.4%
Total Long-Term Liabilities $8.014M $6.474M
YoY Change 23.79% 547.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.733M $8.229M
Total Long-Term Liabilities $8.014M $6.474M
Total Liabilities $17.75M $14.70M
YoY Change 20.7% 54.77%
SHAREHOLDERS EQUITY
Retained Earnings -$273.2M -$183.9M
YoY Change 48.56%
Common Stock $441.9M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $164.6M $244.4M
YoY Change
Total Liabilities & Shareholders Equity $182.3M $259.1M
YoY Change -29.64% 208.86%

Cashflow Statement

Concept 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$23.04M -$16.11M
YoY Change 43.04% 48.96%
Depreciation, Depletion And Amortization $158.0K $132.0K
YoY Change 19.7% 3.13%
Cash From Operating Activities -$22.74M -$17.74M
YoY Change 28.23% 394.29%
INVESTING ACTIVITIES
Capital Expenditures $920.0K $287.0K
YoY Change 220.56% 1204.55%
Acquisitions
YoY Change
Other Investing Activities $30.96M $15.17M
YoY Change 104.14% 173.79%
Cash From Investing Activities $30.04M $14.88M
YoY Change 101.9% 169.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 168.0K 608.0K
YoY Change -72.37% 1221.74%
NET CHANGE
Cash From Operating Activities -22.74M -17.74M
Cash From Investing Activities 30.04M 14.88M
Cash From Financing Activities 168.0K 608.0K
Net Change In Cash 7.131M -2.249M
YoY Change -417.07% -201.08%
FREE CASH FLOW
Cash From Operating Activities -$22.74M -$17.74M
Capital Expenditures $920.0K $287.0K
Free Cash Flow -$23.66M -$18.02M
YoY Change 31.3% 399.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 dei Document Period End Date
DocumentPeriodEndDate
2022-07-31
CY2022Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q3 dei Amendment Flag
AmendmentFlag
false
CY2022Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--04-30
CY2022Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001348911
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q3 dei Document Type
DocumentType
10-Q
CY2022Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q3 dei Entity File Number
EntityFileNumber
001-36830
CY2022Q3 dei City Area Code
CityAreaCode
857
CY2022Q3 dei Local Phone Number
LocalPhoneNumber
999-0075
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24550748
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
25000
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
25000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
441914000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
439104000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-273217000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-250175000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4150000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3861000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
164572000
CY2022Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
8014000
CY2022Q3 dei Entity Registrant Name
EntityRegistrantName
KALVISTA PHARMACEUTICALS, INC.
CY2022Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
7211000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-0915291
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
55 Cambridge Parkway
CY2022Q3 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 901E
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24570872
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24570872
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24550748
CY2022Q3 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2022Q3 dei Trading Symbol
TradingSymbol
KALV
CY2022Q3 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q3 dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24602023
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37863000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30732000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
104212000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
135470000
CY2022Q3 kalv Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
17248000
CY2022Q2 kalv Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
14098000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11084000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13347000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
170407000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
193647000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3030000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2178000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8664000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7862000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
218000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
193000
CY2022Q3 us-gaap Assets
Assets
182319000
CY2022Q2 us-gaap Assets
Assets
203880000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2908000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3638000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5828000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6961000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
997000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
977000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
9733000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11576000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8014000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7211000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
185093000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
182319000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
203880000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18186000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13669000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8130000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5847000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
26316000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
19516000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-26316000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19516000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
242000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
274000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-517000
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-51000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3549000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3184000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3274000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3407000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23042000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-16109000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-403000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
49000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
98000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-129000
CY2022Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-16000
CY2021Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-23000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-289000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-57000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23331000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16166000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.94
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.94
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24557615
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24557615
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24429919
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24429919
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
185093000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
168000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2642000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23042000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-403000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
98000
CY2022Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-16000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
164572000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
257193000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
608000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2795000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-16109000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
49000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-129000
CY2021Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-23000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
244430000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-23042000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-16109000
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
158000
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
132000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2642000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2795000
CY2022Q3 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-16000
CY2021Q3 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-23000
CY2022Q3 kalv Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
23000
CY2021Q3 kalv Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
22000
CY2022Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
391000
CY2021Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
753000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-426000
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-14000
CY2022Q3 kalv Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
3570000
CY2021Q3 kalv Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
3211000
CY2022Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1935000
CY2021Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
625000
CY2022Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-678000
CY2021Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-528000
CY2022Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1043000
CY2021Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1001000
CY2022Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22742000
CY2021Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17735000
CY2022Q3 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
10102000
CY2021Q3 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
19036000
CY2022Q3 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
41066000
CY2021Q3 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
34204000
CY2022Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
920000
CY2021Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
287000
CY2022Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
30044000
CY2021Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14881000
CY2022Q3 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
168000
CY2021Q3 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
608000
CY2022Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
168000
CY2021Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
608000
CY2022Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-339000
CY2021Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-3000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7131000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2249000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30732000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50592000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
37863000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
48343000
CY2022Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1192000
CY2022Q3 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
144000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-273200000
CY2022Q3 kalv Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
142100000
CY2022Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
30695000
CY2022Q3 kalv Cash And Cash Equivalents And Marketable Securities Fair Value Disclosure
CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure
134907000
CY2022Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
13735000
CY2022Q2 kalv Cash And Cash Equivalents And Marketable Securities Fair Value Disclosure
CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure
149205000
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
105228000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
15000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1031000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
104212000
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
136599000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1131000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
135470000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
85071000
CY2022Q3 kalv Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
13265000
CY2022Q3 kalv Available For Sale Securities Debt Maturities After Two Through Four Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughFourYearsFairValue
5876000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
104212000
CY2022Q3 kalv Lessee Operating Lease Liability Minimum Payments Interest Included In Payments
LesseeOperatingLeaseLiabilityMinimumPaymentsInterestIncludedInPayments
2885000
CY2022Q3 kalv Lessee Operating Lease Liability Present Value Of Net Minimum Payments
LesseeOperatingLeaseLiabilityPresentValueOfNetMinimumPayments
9011000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
997000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8014000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2064000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4168000
CY2022Q3 kalv Accrued Research Expense Current
AccruedResearchExpenseCurrent
2503000
CY2022Q2 kalv Accrued Research Expense Current
AccruedResearchExpenseCurrent
2011000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1043000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
474000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
218000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
308000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5828000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6961000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1815000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1854000
CY2022Q3 kalv Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
3431000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
11896000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6709000
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8404000
CY2022Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2334000
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2234000
CY2022Q3 us-gaap Interest Receivable And Other Assets
InterestReceivableAndOtherAssets
463000
CY2022Q2 us-gaap Interest Receivable And Other Assets
InterestReceivableAndOtherAssets
888000
CY2022Q3 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
1578000
CY2022Q2 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
1821000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11084000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13347000
CY2022Q3 kalv Contractual Obligations Remaining Commitment Including Cancellation Provisions
ContractualObligationsRemainingCommitmentIncludingCancellationProvisions
30200000
CY2022Q3 kalv Amount Associated With Indemnification
AmountAssociatedWithIndemnification
0
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1277000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1741000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1778000

Files In Submission

Name View Source Status
0000950170-22-018239-index-headers.html Edgar Link pending
0000950170-22-018239-index.html Edgar Link pending
0000950170-22-018239.txt Edgar Link pending
0000950170-22-018239-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
kalv-20220731.htm Edgar Link pending
kalv-20220731.xsd Edgar Link pending
kalv-ex31_1.htm Edgar Link pending
kalv-ex31_2.htm Edgar Link pending
kalv-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
kalv-20220731_cal.xml Edgar Link unprocessable
kalv-20220731_pre.xml Edgar Link unprocessable
kalv-20220731_lab.xml Edgar Link unprocessable
kalv-20220731_def.xml Edgar Link unprocessable
kalv-20220731_htm.xml Edgar Link completed